


CLAIMS

WHAT IS CLAIMED IS:

1. A compound of Formula (I), or a pharmaceutically acceptable salt, solvate, stereoisomer, or an isotopic variant thereof:



Formula (I);

wherein:

Q^1 is N or CW;

Q^2 and Q^3 are independently N or CW;

each W is independently hydrogen, halogen, -CN, -OR^b, NR^cR^d, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ hydroxyalkyl;

R¹ and R² are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}; or R¹ and R² are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{1b};

each R^{1a} and R^{1b} is independently oxo, halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R³ is hydrogen, halogen, -CN, -OR^b, -SR^b, -NR^cR^d, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{3a};

each R^{3a} is independently oxo, halogen, -CN, -OR^b, -NR^cR^d, -C(=O)R^a, -C(=O)OR^b, -C(=O)NR^cR^d, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R⁴ and R⁵ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^6 is hydrogen, deuterium, halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 deuterioalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl); wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{6a} ; each R^{6a} is oxo, halogen, $-CN$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{14}$, $-NO_2$, $-NR^{15}R^{16}$, $-S(=O)_2R^{14}$, $-NR^{13}S(=O)_2R^{14}$, $-S(=O)_2NR^{15}R^{16}$, $-C(=O)R^{14}$, $-OC(=O)R^{14}$, $-C(=O)OR^{13}$, $-OC(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)NR^{15}R^{16}$, $-NR^{13}C(=O)R^{14}$, $-NR^{13}C(=O)OR^{13}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 deuterioalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R^7 , R^8 , R^9 , and R^{10} are independently hydrogen, deuterium, halogen, $-CN$, $-OR^b$, $-SR^b$, $-NR^cR^d$, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, or heterocycloalkyl;

X is $-S-$, $-O-$, or $-NR^N-$;

R^N is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, cycloalkyl, or heterocycloalkyl;

Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

each R^A is independently oxo, halogen, $-CN$, $-OR^b$, $-SR^b$, $-S(=O)R^a$, $-NO_2$, $-NR^cR^d$, $-S(=O)_2R^a$, $-NR^bS(=O)_2R^a$, $-S(=O)_2NR^cR^d$, $-C(=O)R^a$, $-OC(=O)R^a$, $-C(=O)OR^b$, $-OC(=O)OR^b$, $-C(=O)NR^cR^d$, $-OC(=O)NR^cR^d$, $-NR^bC(=O)NR^cR^d$, $-NR^bC(=O)R^a$, $-NR^bC(=O)OR^b$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

n is 0, 1, 2, 3, or 4;

each R^{13} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 deuterioalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{13a} ;

each R^{14} is independently C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{14a} ;

each R^{15} and R^{16} is independently hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{15a} ;

or R^{15} and R^{16} are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{15b} ;

each R^{13a} , R^{14a} , R^{15a} , and R^{15b} is independently oxo, halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

R^{21} and R^{22} are independently hydrogen, C₁-C₂₀ alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{21a} ;

or R^{21} and R^{22} are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{21b} ;


each R^{21a} and R^{21b} is independently oxo, halogen, -CN, -OR^b, -SR^b, -S(=O)R^a, -NO₂, -NR^cR^d, -S(=O)₂R^a, -NR^bS(=O)₂R^a, -S(=O)₂NR^cR^d, -C(=O)R^a, -OC(=O)R^a, -C(=O)OR^b, -OC(=O)OR^b, -C(=O)NR^cR^d, -OC(=O)NR^cR^d, -NR^bC(=O)NR^cR^d, -NR^bC(=O)R^a, -NR^bC(=O)OR^b, C₁-C₆ alkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl);

each R^a is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo, halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

each R^b is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo, halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl; and

each R^c and R^d is independently hydrogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three oxo, halogen, -OH, C₁-C₆ alkyl, or C₁-C₆ haloalkyl;

or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, or C₁-C₆ hydroxyalkyl;




2. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
Q¹ is N.
3. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
Q¹ is CW.
4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
Q² is N and Q³ is CW.
5. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
Q² is CW and Q³ is N.
6. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
Q² is N and Q³ is N.
7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each W is independently hydrogen, halogen, or C₁-C₆ alkyl.
8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each W is hydrogen.
9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R³ is halogen, C₂-C₆ alkynyl, or C₁-C₆ hydroxyalkyl; wherein each alkyl and alkynyl is independently optionally substituted with one, two, or three R^{3a}.
10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R³ is halogen.
11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R¹ is C₁-C₆ alkyl, C₁-C₆ haloalkyl, cycloalkyl, heterocycloalkyl, C₁-C₆ alkyl(aryl), C₁-C₆ alkyl(heteroaryl), C₁-C₆ alkyl(cycloalkyl), or C₁-C₆ alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{1a}.
12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:

- R¹ is C₁-C₆ alkyl, cycloalkyl, C₁-C₆ alkyl(aryl), or C₁-C₆ alkyl(cycloalkyl); wherein each alkyl, cycloalkyl, and aryl is independently optionally substituted with one, two, or three R^{1a}.
13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R¹ is cycloalkyl optionally substituted with one, two, or three R^{1a}.
14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R¹ is cycloalkyl.
15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{1a} is independently oxo, halogen, -CN, -OR^b, C₁-C₆ alkyl, or C₁-C₆ fluoroalkyl.
16. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
each R^{1a} is independently halogen or C₁-C₆ alkyl.
17. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R² is hydrogen or C₁-C₆ alkyl.
18. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R² is hydrogen.
19. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁴ and R⁵ are independently hydrogen, halogen, -OR^b, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.
20. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁴ and R⁵ are independently hydrogen or -OR^b.
21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁴ and R⁵ are -OH.
22. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
X is -O-.
23. The compound of any one of claims 1-22, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
R⁷, R⁸, R⁹, and R¹⁰ are independently hydrogen, halogen, or C₁-C₆ alkyl.
24. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:


- R^7 , R^8 , R^9 , and R^{10} are hydrogen.
25. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
Ring A is heteroaryl.
26. The compound of any one of claims 1-25, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 n is 0.
27. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^6 is hydrogen, $-C(=O)R^{14}$, $-C(=O)OR^{13}$, $-C(=O)NR^{15}R^{16}$, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C_1 - C_6 alkyl(aryl), C_1 - C_6 alkyl(heteroaryl), C_1 - C_6 alkyl(cycloalkyl), or C_1 - C_6 alkyl(heterocycloalkyl); wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R^{6a} .
28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^6 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, or C_1 - C_6 alkyl(heteroaryl); wherein the alkyl, and heteroaryl is independently optionally substituted with one, two, or three R^{6a} .
29. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^6 is C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 hydroxyalkyl, C_1 - C_6 heteroalkyl, or C_1 - C_6 alkyl(heteroaryl); wherein the alkyl, and heteroaryl is independently optionally substituted with one, two, or three R^{6a} .
30. The compound of any one of claims 1-29, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^6 is C_1 - C_6 hydroxyalkyl or C_1 - C_6 heteroalkyl; wherein the alkyl is independently optionally substituted with one, two, or three R^{6a} .
31. The compound of any one of claims 1-29, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^6 is hydrogen, C_1 - C_6 hydroxyalkyl, or C_1 - C_6 heteroalkyl; wherein the alkyl is independently optionally substituted with one, two, or three R^{6a} .
32. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:
 R^6 is C_1 - C_6 hydroxyalkyl.
33. The compound of any one of claims 1-32, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein:


R^{21} and R^{22} are hydrogen.


34. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein the compound is:




35. A compound, or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, that is:









36. A pharmaceutical composition comprising a compound of any one of claims 1-35, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a pharmaceutically acceptable excipient.
37. A method of inhibiting CD73 comprising contacting CD73 with a compound of any one of claims 1-35, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
38. A method of treating cancer in a subject, comprising administering to the subject a compound of any one of claims 1-35, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
39. A method of treating cancer in a subject, comprising administering to the subject a pharmaceutical composition of claim 36.
40. The method of either of claims 38 or 39, wherein the cancer is lung cancer, melanoma, breast cancer, ovarian cancer, colorectal cancer, gastric cancer, gallbladder cancer, prostate cancer, renal cancer, or a lymphoma.
41. The method of any one of claims 38-40, wherein the cancer expresses CD73.
42. The method of any one of claims 38-40, wherein CD73 is upregulated in the cancer to be treated.
43. The method of any one of claims 38-42, further comprising administering a second therapeutic agent.
44. The method of claim 43, wherein the second therapeutic agent is a chemotherapeutic agent or an immunotherapy agent.
45. A method of treating an infection in a subject, comprising administering to the subject a compound of any one of claims 1-35, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

- 46. A method of treating an infection in a subject, comprising administering to the subject a pharmaceutical composition of claim 36.
- 47. The method of either of claims 45 or 46, wherein the infection is a viral infection.
- 48. The method of either of claims 45 or 46, wherein the infection is a parasitic infection.
- 49. A method of treating a neurodegenerative disease in a subject, comprising administering to the subject a compound of any one of claims 1-35, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- 50. A method of treating a neurodegenerative disease in a subject, comprising administering to the subject a pharmaceutical composition of claim 36.
- 51. The method of either of claims 49 or 50, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, or autism.